Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042041 · ClinicalTrials.gov registry record · Phase 1
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01042041 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 18 participants.
The verdict
NCT01042041, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: This phase I trial is studying side effects and best dose of sorafenib tosylate when given together with chemoembolization in treating patients with unresectable liver cancer.
Interventions
- DRUG cisplatin
- DRUG doxorubicin hydrochloride
- DRUG sorafenib tosylate
- DRUG mitomycin C
- PROCEDURE transarterial chemoembolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01042041
The ClinicalTrials.gov registry entry for NCT01042041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT01042041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01042041 about?
NCT01042041 is a clinical study titled "Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer". RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from d...
What is the current status of trial NCT01042041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01042041?
The interventions under investigation include: cisplatin (DRUG), doxorubicin hydrochloride (DRUG), sorafenib tosylate (DRUG), mitomycin C (DRUG), transarterial chemoembolization (PROCEDURE).
Who is sponsoring clinical trial NCT01042041?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.